WEST LAFAYETTE, Ind. – Officials of Kylin Therapeutics, Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office (USPTO).

“This patent represents new ground recognized in the field of RNA interference,” said Eric Davis, president and CEO of Kylin Therapeutics. “pRNAi is the only self-delivering RNA-based nanoparticle that induces RNA interference to be granted a patent by the USPTO. We are very pleased, not only for our company, but because this type of technology could give physicians a new method for drug delivery in the treatment of diseases including various forms of cancer.”

This issuance follows a notice of allowance made in October of 2009. The patent’s issue date is February 2, 2010. The newly issued patent broadly covers a number of functionalities for Kylin’s lead technology platform, “pRNA”, or “packaging RNA.” These functionalities include receptor binding, ribozyme activity, and RNA-interference. The patent’s principal author is Peixuan Guo, former professor at Purdue University who is now a professor at University of Cincinnati.

About Kylin Therapeutics Inc.

Kylin Therapeutics, Inc. (www.kylintherapeutics.com), a cutting-edge biotechnology company based in the Purdue Research Park, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of oligonucleotides for treatment of many common diseases. Our goal is to use RNA building blocks to build ideal therapeutic nanotechnologies to address unmet medical needs. This visionary platform has enormous potential to combine into one nanoparticle all possible RNA functionalities including receptor antagonism/activation, cell targeting/delivery and gene knockdown through mechanisms like RNA interference. Kylin will unlock the full potential of RNA for the treatment of disease.

Media contact:

Cynthia Sequin, Purdue Research Park, 765-588-3340, casequin@prf.org